- Advertise
- Contact Us
- Editorial Info
- Contribute
- Terms and Conditions
- Privacy Policy
- Do not sell my Personal Information
© 2020 MJH Life Sciences™ and Rheumatology Network. All rights reserved.
Latest Conference Articles
Bisphosphonate Use Associated with Increased Fracture Risk
September 16th 2020
Bisphosphonate use, especially for more than five years, is associated with an increased risk of atypical femoral fractures, but this risk falls considerably after discontinuation, according to a Nationwide Danish an analysis and review presented on September 13 at the American Society for Bone and Mineral Research (ASBMR) annual meeting which was held virtually.
Teriparatide for Bone Formation in Hip Fractures
September 16th 2020
Teriparatide, a recombinant human parathyroid hormone analog [rhPTH(1-34)] approved for women and men with osteoporosis, has been shown to renew bone tissue in patients with femoral neck fractures of the hip, according to research presented at the American Society for Bone and Mineral Research (ASBMR) annual meeting which was held this week.
Zoledronate As Booster Drug in Fight Against Osteoporosis
September 14th 2020
Some evidence shows the combination of teriparatide and denosumab, followed by a single dose of zoledronate, may be an effective strategy in the long-term management of high-risk fragility fractures.
Q&A: Vitamin D and Bone Mineral Density
September 14th 2020
High-dose vitamin D supplementation compared with standard-dose vitamin D supplementation resulted in a greater loss of volumetric bone mineral density in women but not men, according to study data presented at the American Society for Bone and Mineral Research (ASBMR) annual meeting which is being held virtually.
Q&A: Anabolic Agents for Osteoporosis
September 14th 2020
Three months of treatment with the osteoporosis drug abaloparatide (Tymlos, Radius) has a robust effect on bone formation in postmenopausal women with osteoporosis, according to a study presented on Sept. 12 at the American Society for Bone and Mineral Research (ASBMR) annual meeting which is being held virtually.
Sarilumab Shown to Reduce Persistent Pain in RA
September 11th 2020
Report shows that sarilumab may be better at controlling severe and refractory pain in rheumatoid arthritis patients than adalimumab.
JAK1 Inhibitor Filgotinib Meets PsA Safety Profile
September 11th 2020
The investigational JAK inhibitor filgotinib―which is under study as a treatment for a number of rheumatic diseases―has been shown to be safe and well tolerated in psoriatic arthritis patients.
Abaloparatide Shown to Increase Bone Mineral Density
September 11th 2020
The osteoporosis treatment abaloparatide has been shown to increase bone mineral density of the lumbar spine, total hip and femoral neck bone in patients with osteoporosis who are at high risk for fracture, according to a study presented today at the American Society for Bone and Mineral Research annual meeting which is being held virtually through Tuesday.
EULAR Report: Physicians Increasingly Pass on Biosimilars
June 16th 2020
Rheumatologists still lack confidence in prescribing biosimilars, shows study presented at EULAR.
EULAR Report: Nurse-Led Care May Improve RA Patient-Reported Outcomes
June 16th 2020
Rheumatoid arthritis patients receive treatment that is on par with that of a physician, shows a study based on patient-reported outcomes and disease activity. The study was recently reported at the EULAR annual meeting.